Markets:

Overview

News

Currencies

International

Treasuries

Aptose Biosciences, Inc. - Common Shares (NQ:APTO)

1.710 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aptose Biosciences, Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >

Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023

March 09, 2023

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference

March 02, 2023

From Aptose Biosciences, Inc.

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

February 13, 2023

It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to keep a watch on Monday!

Via InvestorPlace

Stocks That Hit 52-Week Lows On Thursday ↗

October 20, 2022

Thursday saw 177 companies set new 52-week lows.

Via Benzinga

Aptose Biosciences: Q2 Earnings Insights ↗

August 02, 2022

Aptose Biosciences (NASDAQ:APTO) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia

January 30, 2023

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference

December 28, 2022

From Aptose Biosciences, Inc.

Via GlobeNewswire

Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket ↗

December 12, 2022

Gainers

Via Benzinga

Aptose Biosciences Establishes New At-The-Market Facility

December 12, 2022

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

December 11, 2022

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th

December 07, 2022

Data to be presented in poster at ASH Annual Meeting

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

November 14, 2022

From Aptose Biosciences, Inc.

Via GlobeNewswire

Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session ↗

November 03, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60.

Via Benzinga

Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday ↗

November 04, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.

Via Benzinga

Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting

November 03, 2022

Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Reports Results for the Third Quarter 2022

November 01, 2022

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022

October 18, 2022

From Aptose Biosciences, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Tuesday ↗

October 25, 2022

On Tuesday, 120 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

October 18, 2022

During Tuesday's session, 78 companies made new 52-week lows.

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

FDA Grants Fast Track designation To Aptose Biosciences for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation ↗

May 04, 2022

Aptose Biosciences Inc. (NASDAQ: APTO) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of...

Via Benzinga

38 Stocks Moving In Wednesday's Mid-Day Session ↗

March 23, 2022

Gainers Allego N.V. (NYSE: ALLG) shares jumped 158.5% to $21.41 after the company announced the completion of its merger agreement with Spartan Acquisition Corp., which resulted...

Via Benzinga

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale ↗

March 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

March 23, 2022

Rise and shine, trader! We're starting off the day with a breakdown of the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

32 Stocks Moving in Wednesday's Pre-Market Session ↗

March 23, 2022

Gainers Zentek Ltd. (NASDAQ: ZTEK) rose 180.5% to $7.63 in pre-market trading after declining around 5% on Tuesday. Creative Realities Inc (NASDAQ: CREX) shares rose 52.6% to $1....

Via Benzinga

Aptose Biosciences: Q4 Earnings Insights ↗

March 23, 2022

Aptose Biosciences (NASDAQ:APTO) reported its Q4 earnings results on Tuesday, March 22, 2022 at 04:01 PM. Here's what investors need to know about the announcement....

Via Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout ↗

March 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For March 22, 2022 ↗

March 22, 2022

Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is projected to report quarterly loss at $0.18 per share on revenue of $338.69 million. • HUYA (...

Via Benzinga

Earnings Preview: Aptose Biosciences ↗

March 21, 2022

Aptose Biosciences (NASDAQ:APTO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-22. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Earnings Outlook For Aptose Biosciences ↗

March 21, 2022

Aptose Biosciences (NASDAQ:APTO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-22. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Oil & Gas Journal starts where other industry publications stop. It delivers more than information; it delivers context, adding details the others leave out and combining them with analysis, commentary, industry trends, and statistics.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/ogjonline

https://www.linkedin.com/company/oil-&-gas-journal

http://twitter.com/ogjonline

Affiliated Brands

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions